View Alert
Versions:


Originator: CMO Messaging

 
From: CMO Messaging

Issue date: Originally issued on 26-May-2020 10:32:37. This version was issued on 26-May-2020 10:32:37

Action by recipients:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

Information to recipients:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • DHSC Supply Disruption - Medicines

Action category: Important information for immediate action

Title: Early Access to Medicines Scheme for remdesivir in the treatment of COVID-19. Implementation of the scheme and management of supply

Broadcast content:

A positive Scientific Opinion for remdesivir in the treatment of COVID-19 has been published by the Medicines and Healthcare Products Regulatory products Agency (MHRA). It advises on the conditions where the technology will be used and commissioned by the NHS.

Hospitals who have registered an interest in participating in COVID-19 Early Access to Medicines Scheme (EAMS) should use the country specific EAMS application process to apply for access to remdesivir for eligible patients.

This alert provides information on medicine supply, access criteria, data collection and implementation.

Updated alert pdf attached to reflect an amendment to the second bullet point in the 'Illness severity and organ support criteria' section.



Additional information: This alert does not need to be cascaded to primary care.

Alert reference: CEM/CMO/2020/025

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency